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Caspase-cleaved proteins are released from disintegrated apoptotic cells and can be detected in the circulation. We here addressed
whether caspase-cleaved cytokeratin 18 (CK18-Asp396) can be used as a serum biomarker for assessment of the clinical efficiency
of chemotherapy in hormone-refractory prostate cancer (HRPC). A total of 82 patients with HRPC were evaluated during
751 treatment cycles, either with estramustine (EMP)/vinorelbine or with EMP/docetaxel. The levels of CK18-Asp396 and of
total CK18 were measured in patient serum before and during therapy by ELISA. Docetaxel induced significant increases in serum
CK18-Asp396 (Po0.0001) and total CK18 (Po0.0002), suggesting induction of apoptosis. Similarly, vinorelbine induced increases in
both CK18-Asp396 and CK18 (Po0.001 and 0.011). In contrast, EMP induced increases in total serum CK18 (Po0.0001), but not
in CK18-Asp396 (P¼0.13). The amplitudes of docetaxel-induced increases were associated with baseline prostate-specific antigen
(PSA) and CK18 serum levels in these patients, consistent with tumoral origin of caspase-cleaved fragments. Docetaxel induced
significant increases in CK18-Asp396 during second-, third- and fourth-line therapy and induced increased levels of CK18-Asp396
during treatment cycles 1–8. In contrast, vinorelbine induced significant increases only during cycles 1–3. In a subgroup of 32 patients
that received EMP/vinorelbine in second line followed by EMP/docetaxel in third line, docetaxel induced stronger increases than
vinorelbine (P¼0.008). These results show that the CK18-Asp396 serum marker can be used to assess tumour apoptosis in vivo and
suggest that the clinical efficiency of docetaxel in HRPC is due to induction of apoptosis during multiple treatment cycles.
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Although treatment of hormone-refractory prostate cancer
(HRPC) is still considered palliative, recent studies have demon-
strated improved overall survival using docetaxel, in combination
with estramustine phosphate (EMP) or prednisone (Petrylak
et al, 2004; Tannock et al, 2004). Docetaxel is a semisynthetic
taxane, a class of anticancer agents that bind to beta tubulin,
thereby stabilising microtubules and inducing cell-cycle arrest
and apoptosis (Hennequin et al, 1995; Pienta, 2001). Estramustine
phosphate is a nornitrogen mustard–estradiol conjugate that was
developed as an alkylating agent specific for oestrogen receptor-
positive cells (Smith, 1999). It has later been shown that EMP
interferes with microtubuli dynamics, whereas the alkylating effect
is insignificant (Smith, 1999). Estramustine phosphate is often
used in combination with vinorelbine (Carles et al, 1998; Smith
et al, 2000), a semisynthetic vinca alkaloid which also inhibits
microtubule assembly (Johnson et al, 1996; Oudard et al, 2001).
Similar to other types of chemotherapy, prostate cancer
treatment is based on combinations of drugs that are administered
during repetetive cycles and at various stages of clinical
progression. The response to treatment is commonly evaluated
using the tumour marker PSA (prostate-specific antigen). Prostate-
specific antigen levels have been reported to correlate with tumour
volume (Partin et al, 1990) and pathological stage (Oesterling et al,
1988). The overall benefit of monitoring serum PSA after treatment
for prostate cancer is, however, controversial (Thalmann et al,
1996; Kramer et al, 1997; Vicini et al, 2005). In the recent TAX327
study, the rates of PSA response and patients survival were
discordant between two docetaxel groups (Tannock et al, 2004).
Noninvasive assessment of treatment-induced tumour cell death
is desirable both for accurate management of patients and
for detailed characterisation of different treatment modalities. It
is desirable to assess whether all drugs in different combinations
are effective and to determine for how many cycles it is meaningful
to treat patients before resistance has developed. Cytokeratin 18
(CK18) is a suitable serum biomarker for non-invasive determina-
tion of apoptosis of epithelial cells (Linder et al, 2004). Cytokeratin
18 is an abundant intracellular protein that is cleaved by caspases
during apoptosis, and preclinical and clinical studies have shown
that caspase-cleaved CK18 fragments are released from apoptotic
cells into the extracellular compartment (Kramer et al, 2004;
Linder et al, 2004). In contrast to other serum biomarkers used
to assess tissue damage during cancer treatment such as cyto-
chrome c (Renz et al, 2001) and nucleosomal DNA (Holdenrieder
et al, 2001), caspase-cleaved CK18 is produced only during apop-
tosis and only by epithelially derived cells. Chemotherapy-sensitive
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scells of the bone marrow do not express CK18. We here used
measurements of caspase-cleavage products of CK18 in patient
serum to assess the efficiency of different anticancer drugs during
prostate cancer treatment. We demonstrate that docetaxel induces
significantly increased levels of caspase-cleaved CK18 in patient
serum at both early and late stages of prostate cancer progression.
PATIENTS AND METHODS
Patients
A total of 82 patients with HRPC were included. Of these, 71
patients were selected for second-line chemotherapy based on
two or more consecutive increases in PSA not o14 days apart and/
or objective progression of metastases in bone or computed
tomography (CT) scan in a state of surgical or chemical castration
(Table 1). Antiandrogen therapy was discontinued 44 weeks
before inclusion (46 weeks for bicalutamide). Continued evidence
of disease progression was required after anti-androgen with-
drawal. In total, 62 patients received sequential chemotherapy with
EMP and vinorelbine, and nine patients with EMP and docetaxel.
In 32 patients, who progressed on EMP/vinorelbine, treatment
was switched to third-line chemotherapy with EMP/docetaxel. In
one patient who progressed on third line EMP/docetaxel treatment
was switched to EMP/vinorelbine again. In addition to these 71
patients, 11 patients were referred to the Department of Urology,
Vienna, for third line EMP/vinorelbine. Ethical approval and
consent was obtained for collection of serum samples.
Chemotherapeutic regimen
Chemotherapy consisted of sequential application of 300mg EMP
intravenously from day 1 to day 3 and vinorelbine (Navelbine
R;
30mgm
 2) or docetaxel (Taxotere
R;6 0 m g m
 2) on day 5. This
regimen was repeated every 3 weeks.
Assessment of apoptosis
Serum samples were collected and frozen at  701C. Samples
were collected at day 1, 3, 5 and 7 during therapy. A total of 751
cycles were analysed. Blood was not available for all time points
(2602 samples were available, yielding a coverage of 87%). Samples
were assayed in duplicate for caspase-cleaved CK18 using the
M30-Apoptosenset ELISA kit (PEVIVA AB, Bromma, Sweden)
and for total soluble CK18 using the M65-ELISA kit (PEVIVA) as
recommended by the manufacturer.
Statistics
The data sets obtained were not normally distributed and
nonparametric statistics were used throughout this study.
The Wilcoxon matched-pairs signed-ranks test was used to analyse
whether statistically significant increases in CK18 levels occurred
during therapy (pairwise comparisons of pre- and post-treatment
values). The levels of CK18 are presented as median values with
25–75% spreads. The Wilcoxon two-sample test was used to
calculate whether differences in the median levels of CK18 were
statistically significant.
RESULTS
Increases in the serum levels of caspase-cleaved CK18
fragments during chemotherapy of prostate cancer
patients
A total of 82 patients with HRPC were treated with a combination
of EMP and vinorelbine, or with EMP and docetaxel, mainly as
second- or third-line therapy following hormone ablation (Table 1).
Estramustine phosphate was administered on days 1, 2 and 3 (751
therapy cycles evaluated); vinorelbine or docetaxel was adminis-
tered on day 5 (462 and 289 cycles evaluated, respectively).
Caspase-cleaved CK18 fragments (CK18-Asp396; CK18 molecules
cleaved at Asp396) were measured in patient serum using the
M30-Apoptosense
TM ELISA (Kramer et al, 2004). We also
measured total serum CK18 using the M65-ELISA (Kramer et al,
2004). In vitro experiments and experiments using mouse
xenografts showed maximal release of CK18 molecules at 48h
after drug treatment (Ueno et al, 2003; Kramer et al, 2004) (our
unpublished data). We therefore evaluated the response to EMP
between day 1 (prior to therapy) and day 3, and the response to
vinorelbine or docetaxel between days 5 and 7.
Table 1 Clinical parameters relevant to this study
All patients EMP+vinorelbine EMP+docetaxel
Patient characteristics
Age of patients (years) 69 (48–88) 70 (48–87) 69 (49–88)
Time from diagnosis to treatment (months) 66 (7–330) 65 (7–324) 68 (10–330)
Lymph metastasis
a 29 (36%) 21 (29%) 8 (88%)
Bone metastasis
a 44 (54%) 42 (58%) 2 (22%)
Lung metastasis
a 6 (7.3%) 1 (1.4%) 5 (55%)
Liver metastasis
a 5 (6.1%) 5 (6.8%) 0
Second line Third line Fourth line
Treatment Patients Cycles Patients Cycles Patients Cycles
Number of patients and therapy cycles analysed
b
EMP+docetaxel 9 74 32 193 4 21
EMP+vinorelbine 62 404 11 54 1 5
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5
PSA levels during consecutive treatment of 32 patients with vinorelbine and docetaxel (median (25th–75th percentile); ngml
 1)
Second line EMP+vinorelbine 68 (20–116) (100%) 47 (26–145) (69%) 49 (12–103) (72%) 29 (9–73) (43%) 33 (11–80) (49%)
Third line EMP+docetaxel 104(27–162) (100%) 87 (18–132) (84%) 38 (11–107) (37%) 53 (24–123) (51%) 53 (23–173) (51%)
aPresence of metastases at the initiation of chemotherapy.
bTotal patients: 82 (several patients received more than one type of treatment). EMP¼estramustine phosphate;
PSA¼prostate-specific antigen.
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sDocetaxel induced increases in CK18-Asp396 in 71% of all
evaluated treatment cycles, vinorelbine in 65% and EMP in 50%.
The Wilcoxon matched-pairs signed-ranks Test was used to
examine the possible statistical significance of increases in serum
CK18 molecules by different agents. Estramustine phosphate did
not produce significant increases in CK18-Asp396 (P¼0.13),
whereas highly significant increases in total CK18 were observed
(Po0.0001). Highly significant increases in CK18-Asp396 were
induced by docetaxel (Po0.0001) and by vinorelbine (Po0.001).
Similarly, significant increases in total CK18 were induced by
docetaxel (Po0.0002) and by vinorelbine (Po0.011).
To obtain quantitative data with regard to the amplitudes
of CK18 alterations, median serum CK18 levels were compared
before and after onset of treatment. The Wilcoxon two-sample test
was used to determine whether differences in the medians were
statistically significant. Neither EMP nor vinorelbine induced
significant increases in the serum CK18-Asp396 or CK18 by this
test (Table 2). In contrast, docetaxel induced a median increase
of CK18-Asp396 of 18.7% (P¼0.015). An increase of a similar
amplitude (21.4%) was observed for total CK18 (P¼0.014)
(Table 2). Data were also analysed as increases from pretreatment
levels (Figure 1). Only cycles from which both pre- and post-
treatment sera were available were included. The result differed
only marginally from those presented in Table 2 (based on all data
points available). The higher increases of CK18-Asp396 and total
CK18 induced by docetaxel compared to other agents were highly
significant (Figure 1).
Since patients were treated with a combination of EMP and
vinorelbine (or docetaxel) in each treatment cycle, we assessed
whether there was an association between the alterations in serum
CK18 during these types of treatments. No significant correlation
between CK18-Asp396 (or CK18) increases on day 1–3 and on day
5–7 were observed (either for EMP to vinorelbine or EMP to
docetaxel), suggesting different mechanisms of cell sensitivity to
these agents.
Increases in CK18-Asp396 during docetaxel and
vinorelbine therapy are associated with baseline levels
of PSA and CK18
Increases of serum CK18-Asp396 and CK18 levels during therapy
could be due to release from dead tumour cells, from normal
epithelial cells or from both tumour and normal cells. If CK18
molecules are released from tumour cells during therapy, higher
increases (in absolute numbers) are expected in patients with large
tumour loads. If, however, CK18 is released as a consequence of
toxicity to normal epithelial tissue, increases will not correlate to
tumour load. Prostate-specific antigen levels reflect prostate
tumour volume, although other factors such as hormonal
influences also determine these levels (Crawford et al, 1996).
Cytokeratin 18 levels, measured with the TPS test, also correlate to
prostate cancer tumour load (Tarle et al, 1993), and pretreatment
CK18-Asp396 levels correlate to tumour load in breast cancer
patients (Ueno et al, 2003). Significant associations were observed
between the amplitudes of docetaxel-induced increases of CK18-
Asp396 and baseline levels of PSA, CK18 and CK18-Asp396
(comparing the medians of the highest and lowest quartiles)
(Table 3). Significant associations were also observed between
docetaxel-induced increases of CK18 and baseline levels of CK18,
but not with PSA or CK18-Asp396. These findings suggest an
association between docetaxel-induced increases in serum
CK18-Asp396 and the presence of tumour. In contrast, vinor-
elbine- or EMP-induced increases in CK18-Asp396 did not
show significant associations to baseline levels of PSA, CK18 and
CK18-Asp396 (Table 3).
Increases in CK18-Asp396 levels during second-line
vinorelbine and third-line docetaxel treatment
The data in Table 2 suggest that docetaxel induces stronger
increases in serum CK18 than vinorelbine. The present study was,
however, not randomised between docetaxel and vinorelbine. We
analysed the response to docetaxel and vinorelbine in a subgroup
of 32 patients that received both drugs, vinorelbine in second line
(169 cycles) followed by docetaxel in third line (158 cycles). The
alterations from baseline levels were analysed. Monitoring serum
PSA indicated that docetaxel was more efficient than vinorelbine
Table 2 CK18 serum levels during chemotherapy
CK18-Asp396 CK18
Day (Ul
 1)% D
a (Ul
 1)% D
EMP (n¼751 cycles)
1 102 (59–163)
b 0 280 (169–457) 0
3 101 (63–158)  1.0 303 (184–455) 8.2
Docetaxel (n¼289 cycles)
5 123 (86–171) 0 337 (227–514) 0
7 146 (101–229) 18.7 409 (263–595) 21.4
(P¼0.015) (P¼0.014)
Vinorelbine (n¼462 cycles)
5 83 (53–135) 0 255 (165–419) 0
7 89 (58–159) 7.2 272 (166–451) 6.7
aPercent change: from day 1 to day 3 and from day 5 to day 7.
bMedian (25th–75th
percentile). CK18¼Cytokeratin 18; EMP¼estramustine phosphate.
P < 0.0001 P = 0.0003
50
100
0
−50
100
200
100
CK18-Asp396 CK18
EMP VIN
U L−1
P < 0.0001 P < 0.0001
DOC EMP VIN DOC
Figure 1 Alterations of serum CK18-Asp396 and CK18 during
chemotherapy. Box plots (median with 25th and 75th percentiles) of
alterations of pretreatment levels and levels measured after 48h (days 1–3
for EMP (629 EMP cycles) are shown; days 5–7 for docetaxel (224 cycles)
and vinorelbine (343 cycles)). Serum levels of caspase-cleaved CK18
(CK18-Asp396) and CK18 were measured by ELISA.
Caspase-cleaved CK18 in HRPC serum
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s(Table 1). Consistent with the higher efficiacy of docetaxel, a 5.3%
increase in serum CK18-Asp396 was observed in second line
and a 16.2% increase in third line in these 32 patients (Table 4).
The higher increase by docetaxel was statistically significant
(P¼0.008). A similar result was observed for total CK18. The
response to EMP was in the range of 3–5% increase of CK18-
Asp396 and CK18 in these patients during second- and third-line
treatment. Higher baseline levels were observed in DOC-treated
patients, probably reflecting more advanced disease of patients
treated in third line. Although higher baseline levels lead to higher
increases of CK18-Asp396, the increases do not vary as expressed
as percent of baseline.
Figure 2A shows a liver metastasis that increased in size from 2.7
to 3.9cm during treatment with EMP and vinorelbine. Serum PSA
levels increased in parallel (Figure 2B) and CK18-Asp396 increases
during chemotherapy were low (Figure 2B). After changing
therapy to EMP and docetaxel, the lesion decreased from 3.9 to
2cm and PSA levels decreased dramatically. Stronger increases in
CK18-Asp396 levels were observed during EMP and docetaxel
therapy (Figure 2B).
Patterns of CK18-Asp396 increases during therapy
Docetaxel was used as second-line, third-line and fourth-line
therapy. Significant increases of serum CK18-Asp396 were
observed irrespectively of whether docetaxel was used early or
late during clinical progression (Po0.004, Po0.0002 and
Po0.02 at second-, third- and fourth-line therapy, respectively;
Wilcoxon matched-pairs signed-ranks test). Vinorelbine induced
significant increase in CK18-Asp396 during second-line therapy
(Po0.005), whereas the increases during third line were of
borderline significance (P¼0.048). Median increases are shown
in Table 5.
We finally examined treatment-induced levels of CK18-Asp396
at different treatment cycles. Significant increases in CK18-Asp396
were observed during cycles 1–8 (Table 6). In contrast, significant
increases in CK18-Asp396 were observed only during early
vinorelbine treatment cycles (cycles 1–3), but not at later cycles
(Table 6).
DISCUSSION
Docetaxel and vinorelbine have previously been reported to induce
apoptosis of human prostate cancer cells in vitro (Zelivianski et al,
2003). In contrast, apoptosis could not be demonstrated in a
docetaxel-treated human prostate cancer xenograft (Oudard et al,
2003). We here report that both docetaxel and vinorelbine induce
significant increases in serum CK18-Asp396 in HRPC patients.
For docetaxel, the amplitudes of increases were associated with
the baseline serum levels of PSA and CK18 prior to therapy.
This association is not expected if increases are due to toxicity
to normal epithelial cells, but are expected if the fragments
are generated by apoptosis of tumour cells. The fraction of CK18
cleaved by caspases was approximately one-third of total
CK18 both at baseline and after 48h of therapy, suggesting that
both basal and induced serum CK18 reflect apoptosis.
Similar to docetaxel, vinorelbine induced increases of CK18-
Asp396 and CK18. In contrast to docetaxel, vinorelbine-induced
increases in CK18 molecules were not significantly associated with
baseline levels of PSA or CK18. Vinorelbine may therefore be
speculated to induce toxicity to nontumour tissue. Alternatively,
the increases in CK18 molecules do in fact represent tumour
apoptosis, and the lack of association with basal level of PSA/CK18
is due to the relatively low increases in CK18-Asp396 induced by
vinorelbine. Vinorelbine induced CK18-Asp396 increases during
Table 3 Association between treatment-induced increases of CK18-Asp396 and CK18 and baseline levels of PSA, CK18 or CK18-Asp396
Baseline PSA
CK18-Asp396 increase
(Ul
 1) docetaxel
CK18 increase
(Ul
 1) docetaxel
CK18-Asp396 increase
(Ul
 1) vinorelbine
CK18 increase
(Ul
 1) vinorelbine
CK18 increase (Ul 1)
EMP
First quartile 13 ( 4–50) 53 ( 1–183) 7 ( 4–36) 0 ( 54–68) 23 ( 21–87)
Second quartile 24 (2–66) 62 (4–148) 9 ( 11–25) 7 ( 46–85)  1(  83–53)
Third quartile 22 ( 4–55) 50 ( 16–187) 10 ( 11–43) 13 ( 50–90) 22 ( 54–79)
Fourth quartile 82 ( 23–126) P¼0.02
a 47 ( 48–237) 7 ( 3–35) 22 ( 60–321) P¼0.10  7(  144–124)
Baseline CK18
First quartile 22 (0–53) 22 ( 23–152) 7 ( 10–26) 0 ( 48–63) 30 ( 14–86)
Second quartile 18 (0–53) 61 ( 27–165) 6 ( 8–20) 20 ( 14–90) 11 ( 33–73)
Third quartile 13 ( 13–47) 21 ( 19–121) 14 ( 2–45) 7 ( 46–86) 0 ( 84–62)
Fourth quartile 92 (15–169) P¼0.0002 136 (10–423) P¼0.006 7 ( 6–49) 24 ( 96–130) P¼0.31  59 ( 251–124)
Baseline CK18-Asp396
First quartile 13 ( 1–43) 16 ( 30–108) 7 ( 6–19) 4 ( 52–64) 29 ( 28–83)
Second quartile 11 ( 4–46) 56 ( 34–123) 7 ( 8–31) 3 ( 37–95) 2 ( 54–67)
Third quartile 42 (0–91) 97 (1– 216) 6 ( 7–31) 12 ( 57–104)  2(  110–75)
Fourth quartile 54 (1–151) P¼0.004 87 ( 3–232) P¼0.06 16 ( 7–81) P¼0.08 38 ( 69–136) P¼0.15 14 ( 116–117)
aWilcoxon Two-Sample test; comparing the median level of the lowest and highest quartile. CK18¼Cytokeratin 18; PSA¼prostate-specific antigen.
Table 4 Alterations of CK18-Asp396 in patients first treated with EMP/vinorelbine and then with EMP/docetaxel
Increase in CK18-Asp396 Increase in CK18
Second vinorelbine Third docetaxel Second vinorelbine Third docetaxel
(days 1–3) (days 5–7) (days 1–3) (days 5–7) (days 1–3) (days 5–7) (days 1–3) (days 5–7)
2(  27–14)
a 5(  11–29) 6 ( 27–44) 22 ( 1–54) 9 ( 58–67) 0 ( 47–68) 9 ( 67–79) 50 ( 4–76)
2.7%
b 6.7% 5.1% 18.6% 4.1% 0% 2.8% 15.7%
aAlterations expressed in Ul
 1.
bAlterations expressed as percent of base line at day 1 or 5. CK18¼Cytokeratin 18; EMP¼estramustine phosphate.
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scycles 1–3, but not later at later cycles, a pattern that is difficult to
explain by toxicity to normal cells. During cycles 1–3, we observed
an association between CK18-Asp396 and baseline CK18 increases
(lowest and highest CK18 quartile; P¼0.015), but not to baseline
PSA (corresponding P-value: 0.11). In distinction from docetaxel
and vinorelbine, EMP did not induce increases in CK18-Asp396,
but did induce increases in total CK18. Estramustine phosphate-
induced CK18 increases were not associated with basal levels of
PSA or CK18 and EMP did not show a clear pattern as to at which
cycles the CK18 increases occurred (not shown). It is therefore
possible that EMP-induced CK18 increases represent toxicity to
normal tissue. Estramustine phosphate is almost exclusively used
in combination with other drugs, and it is uncertain whether
EMP has significant antitumour activity in these combinations
(Kitamura et al, 2002). Estramustine phosphate has been tested in
combination with docetaxel in a prostate carcinoma xenograft
model, and was not found to increase the efficiency of docetaxel
(Fizazi et al, 2004). Docetaxel and estramustine combinations
induce significant cardiovascular and gastrointestinal toxicity, and
the use of estramustine has been questioned (Armstrong and
Carducci, 2005).
Prostate-specific antigen response rates of above 60% have been
reported for EMP and docetaxel (Petrylak et al, 1999; Savarese
et al, 2001), compared to 24% for EMP and vinorelbine (Smith
et al, 2000). Recent studies have shown that docetaxel-based
therapies lead to improved survival compared to mitoxantrone-
based therapy (Petrylak et al, 2004; Tannock et al, 2004).
We report significant increases in CK18-Asp396 during second-,
Prechemotherapy Second-line EMP/vinorelbine A
B
13571 5713 1357 57 1357
Cyc 1 Cyc 2 Cyc 3 Cyc 4 Cyc 5
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Figure 2 Levels of serum CK18-Asp396 in a patient with HRPC during second- and third-line chemotherapy. The patient (75 years old) had only
detectable liver metastases (a reference lesion is shown in (A) by a multiphasic spiral CT scan with intravenous contrast media of the liver). In spite of five
cycles of EMP/vinorelbine treatment in second line, liver metastases increased in number and size (before therapy shown in left panel of (A), after therapy in
middle panel). Accordingly, serum PSA levels increased (dotted line in B). After switching to five cycles of EMP/docetaxel, a significant reduction in tumour
volume (reference lesion shown in the right panel of (A)) and serum PSA levels was observed (B). Strong increases in CK18-Asp396 (solid line in (B)) were
observed 48h after docetaxel treatment (day 7) of these cycles.
Table 5 Alterations of CK18-Asp396 during second-, third- and fourth-line docetaxel therapy
CK18-Asp396 increase (days 5–7) CK18 increase (days 5–7)
(Ul
 1) Percent increase (Ul
 1) Percent increase (n
a)
Second docetaxel 49 (0–115)
b 31.7 93 ( 21–236) 18.3 54/54
Third docetaxel 22 (0–54) 16.1 47 ( 4–163) 15.0 154/155
Fourth docetaxel 34 (13–98) 29.3 72 (2–202) 30.8 14/15
a(CK18-Asp396/CK18).
bMedian (25th–75th percentile) alterations from day 5 to day 7. CK18¼Cytokeratin 18.
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sthird- and fouth-line docetaxel treatment, suggesting that the agent
is effective in patients with advanced disease. In fact, higher
CK18-Asp396 increases were observed during third-line docetaxel
treatment compared to second-line vinorelbine treatment in the
same group of 32 patients. The high efficiency of docetaxel
appeared to be related to apoptosis induction during a number
of consequtive treatment cycles (at least eight), compared to only
three cycles for vinorelbine. It will be of interest to examine
whether less-toxic docetaxel treatment modalities (lower doses
given weekly) will induce similar levels of CK18-Asp396 as
traditional schedules (Engels and Verweij, 2005).
The median increase in CK18-Asp396 during docetaxel therapy
was 23Ul
 1 (B20% increase). The spread was considerable, with a
10th percentile of  22Ul
 1 and a 90th percentile of 151Ul
 1. The
large individual variations in CK18-Asp396 increases are likely to
be due to differences in apoptosis induction in different tumours.
Whether such differences can be used to predict individual patient
outcome is uncertain at this point. Chemotherapy has traditionally
been used palliatively in HRPC, and although docetaxel has
recently been demonstrated to confer a survival benefit in this
disease, the increased survival time is only approximately 3
months (Petrylak et al, 2004; Tannock et al, 2004). It is unlikely
that differences in apoptosis induction will be reflected in major
differences in patient survival in this group of patients. In general,
it is uncertain whether measurements of tumour cell death in vivo
(by imaging, serum biomarkers or by other methods) will be
strictly correlated to patient survival. Therapy may induce cell
death of subpopulations of sensitive cells, whereas other cell
populations continue to proliferate, leading to clinical failure.
Nevertheless, the possibility to assess tumour apoptosis in serum
of patients with advanced disease is very likely to be of
considerable value for clinical decisions. Furthermore, these
measurements are expected to be useful for demonstration of
drug effects in early phase clinical trials.
Nucleosomes and cytochrome c represent other blood bio-
markers for tissue damage (Holdenrieder and Stieber, 2004). These
biomarkers are not released specifically from epithelial cells, and
their levels in circulation are likely to reflect cell death of all
chemotherapy-sensitive tissues. A recent study showed lower levels
of circulating nucleosomal DNA in responding non-small lung
cancer patients during chemotherapy (assessed as area under the
curve between days 1 and 8) (Holdenrieder et al, 2004). We have
not evaluated our data as an integrated measure of total release,
but analysed increases during the course of treatment. An
intriguing possibility is that combinations of blood biomarkers,
which measure cell death in different cell populations (ideally
tumour cells vs normal cells), can be used to achieve optimal
dosing of anticancer drugs.
The present data suggest that serum CK18 measurements may
be useful for assessing treatment effects. This method is
inexpensive and sera can be frozen and stored before analysis
(Cummings et al, 2005), making the method suitable for multi-
centre clinical trials. Measurements of caspase-cleaved CK18 in
serum may be quite useful for comparisons of the efficiencies
between different treatment modalities, which is a key issue during
development of novel anticancer drugs.
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